149 related articles for article (PubMed ID: 22356621)
1. Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking.
Smith RJ; Aston-Jones G
Eur J Neurosci; 2012 Mar; 35(5):798-804. PubMed ID: 22356621
[TBL] [Abstract][Full Text] [Related]
2. Orexin-1 receptor antagonism does not reduce the rewarding potency of cocaine in Swiss-Webster mice.
Riday TT; Fish EW; Robinson JE; Jarrett TM; McGuigan MM; Malanga CJ
Brain Res; 2012 Jan; 1431():53-61. PubMed ID: 22133306
[TBL] [Abstract][Full Text] [Related]
3. Hypocretin/orexin antagonists decrease cocaine self-administration by female rhesus monkeys.
Foltin RW; Evans SM
Drug Alcohol Depend; 2018 Jul; 188():318-327. PubMed ID: 29852449
[TBL] [Abstract][Full Text] [Related]
4. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil.
Mohammadkhani A; James MH; Pantazis CB; Aston-Jones G
Brain Res; 2020 Mar; 1731():146461. PubMed ID: 31526801
[TBL] [Abstract][Full Text] [Related]
5. Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse to heroin-seeking in rats.
Zhou Y; Leri F; Cummins E; Kreek MJ
Physiol Behav; 2015 Feb; 139():127-35. PubMed ID: 25446223
[TBL] [Abstract][Full Text] [Related]
6. Intraventricular administration of neuropeptide S has reward-like effects.
Cao J; de Lecea L; Ikemoto S
Eur J Pharmacol; 2011 May; 658(1):16-21. PubMed ID: 21349268
[TBL] [Abstract][Full Text] [Related]
7. The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic pain.
Jeong Y; Holden JE
Neuroscience; 2009 Apr; 159(4):1414-21. PubMed ID: 19409203
[TBL] [Abstract][Full Text] [Related]
8. The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle.
Dias MB; Li A; Nattie E
Respir Physiol Neurobiol; 2010 Jan; 170(1):96-102. PubMed ID: 19995618
[TBL] [Abstract][Full Text] [Related]
9. Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats.
Bergamini G; Durkin S; Steiner MA
J Psychopharmacol; 2024 Mar; 38(3):305-308. PubMed ID: 38327032
[TBL] [Abstract][Full Text] [Related]
10. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.
Schmeichel BE; Barbier E; Misra KK; Contet C; Schlosburg JE; Grigoriadis D; Williams JP; Karlsson C; Pitcairn C; Heilig M; Koob GF; Vendruscolo LF
Neuropsychopharmacology; 2015 Mar; 40(5):1123-9. PubMed ID: 25367502
[TBL] [Abstract][Full Text] [Related]
11. Long-term impact of acute restraint stress on heroin self-administration, reinstatement, and stress reactivity.
Carter JS; Kearns AM; Vollmer KM; Garcia-Keller C; Weber RA; Baker NL; Kalivas PW; Reichel CM
Psychopharmacology (Berl); 2020 Jun; 237(6):1709-1721. PubMed ID: 32125483
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.
Douton JE; Horvath N; Mills-Huffnagle S; Nyland JE; Hajnal A; Grigson PS
Addict Biol; 2022 Mar; 27(2):e13117. PubMed ID: 34802173
[TBL] [Abstract][Full Text] [Related]
13. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?
James MH; Mahler SV; Moorman DE; Aston-Jones G
Curr Top Behav Neurosci; 2017; 33():247-281. PubMed ID: 28012090
[TBL] [Abstract][Full Text] [Related]
14. Exposure to environmental enrichment attenuates addiction-like behavior and alters molecular effects of heroin self-administration in rats.
Imperio CG; McFalls AJ; Hadad N; Blanco-Berdugo L; Masser DR; Colechio EM; Coffey AA; Bixler GV; Stanford DR; Vrana KE; Grigson PS; Freeman WM
Neuropharmacology; 2018 Sep; 139():26-40. PubMed ID: 29964093
[TBL] [Abstract][Full Text] [Related]
15. Regulation of histone acetylation by garcinol blocks the reconsolidation of heroin-associated memory.
Cheng J; Wang B; Hu H; Lin X; Liu Y; Lin J; Zhang J; Niu S; Yan J
Biomed Pharmacother; 2024 Apr; 173():116414. PubMed ID: 38460374
[TBL] [Abstract][Full Text] [Related]
16. Orexin-1 receptor signaling increases motivation for cocaine-associated cues.
Bentzley BS; Aston-Jones G
Eur J Neurosci; 2015 May; 41(9):1149-56. PubMed ID: 25754681
[TBL] [Abstract][Full Text] [Related]
17. Multiple roles for orexin/hypocretin in addiction.
Mahler SV; Smith RJ; Moorman DE; Sartor GC; Aston-Jones G
Prog Brain Res; 2012; 198():79-121. PubMed ID: 22813971
[TBL] [Abstract][Full Text] [Related]
18. Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement.
Illenberger JM; Flores-Ramirez FJ; Pascasio G; Matzeu A; Martin-Fardon R
Neuropharmacology; 2023 Nov; 239():109685. PubMed ID: 37579870
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats.
Illenberger JM; Flores-Ramirez FJ; Matzeu A; Mason BJ; Martin-Fardon R
Front Pharmacol; 2023; 14():1127735. PubMed ID: 37180716
[No Abstract] [Full Text] [Related]
20. Neural circuits controlling choice behavior in opioid addiction.
Chang VN; Peters J
Neuropharmacology; 2023 Mar; 226():109407. PubMed ID: 36592884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
